Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2015

View Archived Issues

Heat Biologics begins trial combining HS-110 and PD-1 checkpoint inhibitor in NSCLC

Corbus initiates phase II trial of Resunab for systemic sclerosis

Daktari Diagnostics and Merck & Co. to collaborate on point-of-care HCV test

Ono Pharmaceuticals presents EP2 receptor agonists

RXi Pharmaceuticals plans clinical studies of RXI-109 in ophthalmic scarring

Essex Bio-Technology and Tasly Pharmaceutical collaborate on recombinant protein drugs

Viking Therapeutics begins trial of VK-5211 for acute hip fracture

Amgen and Novartis establish neuroscience collaboration in Alzheimer's disease and migraine

CHDI-003402346, a new clinical candidate for HD

Dicerna Pharmaceuticals submits IND application to FDA for DCR-PH1

FDA approves Varubi for nausea and vomiting associated with cancer chemotherapy

GS-6615 shows short-term efficacy for the treatment of arrhythmia

FDA grants orphan drug designation to LOXO-101

Nissan Chemical Industries ends license agreement with Teijin Pharma and BMS for NTC-801

Novartis receives E.U. approval for Revolade in severe aplastic anemia

Bristol-Myers Squibb discloses anti-HIV macrocycles

Janssen introduces anti-HBV agents

Takeda introduces enteropeptidase inhibitors

Merck KGaA divulges dual p70S6K/Akt inhibitors

Incyte patents LSD1 inhibitors

Suven's 5-HT4 receptor agonist for cognitive dysfunction enters phase I

Avycaz demonstrates efficacy in phase III trial in cUTI

Amgen files MAA for etelcalcetide in secondary hyperparathyroidism

Reduced dose of IL-37 attenuates arterial calcification

FDA grants fast track designation to intravenous iclaprim

FDA issues new approval for Emend

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...